D
Vanda Pharmaceuticals Inc. VNDA
$4.96 $0.010.20%
Recommendation
Sell
Prev Close
$4.95
Volume
27,556
Avg Vol (90D)
666,211
Market Cap
$288.66M
Dividend & Yield
--
52-Week Range
$3.71 - $6.75
P/E (TTM)
--
EPS (TTM)
-$0.3332
My Lists My Alerts
Rating
Reward
D
Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Pass Above 200-Day Moving Average - Here's What Happened
3/13/2025 - MarketBeat
Implied GSSC Analyst Target Price: $85
3/10/2025 - ETF Channel
Vanda Pharmaceuticals (VNDA, $4.91) RSI Indicator left the overbought zone on March 06, 2025
3/7/2025 - Tickeron - Technical Analysis
Vanda Pharmaceuticals (VNDA, $4.91) RSI Indicator left the overbought zone on March 06, 2025
3/7/2025 - Tickeron - Stocks
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA)
3/7/2025 - GuruFocus
Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 10,000 Shares of Stock
3/6/2025 - MarketBeat
Vanda Pharmaceuticals (VNDA, $5.13) price may drop as it broke higher Bollinger Band on Mar 05, 2025
3/6/2025 - Tickeron - Stocks
Vanda Pharmaceuticals (VNDA, $5.13) RSI Indicator left the overbought zone on March 05, 2025
3/6/2025 - Tickeron - Stocks
Vanda Pharmaceuticals (VNDA, $5.13) price may drop as it broke higher Bollinger Band on Mar 05, 2025
3/6/2025 - Tickeron - Stocks
Vanda Pharmaceuticals (VNDA, $5.13) RSI Indicator left the overbought zone on March 05, 2025
3/6/2025 - Tickeron - Stocks
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Acquires 10,000 Shares
3/6/2025 - MarketBeat
Vanda Pharmaceuticals (VNDA, $5.13) RSI Indicator left the overbought zone on March 05, 2025
3/6/2025 - Tickeron - Stocks
Vanda Pharmaceuticals (VNDA, $5.13) price may drop as it broke higher Bollinger Band on Mar 05, 2025
3/6/2025 - Tickeron - Technical Analysis
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA)
3/6/2025 - GuruFocus
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Buys $50,200.00 in Stock
3/5/2025 - Ticker Report
VNDA Makes Bullish Cross Above Critical Moving Average
3/5/2025 - Market News Video
Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Buys 10,000 Shares of Stock
3/2/2025 - MarketBeat
Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of Stock
3/1/2025 - MarketBeat
Insider Buying: Mihael Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc (VNDA)
3/1/2025 - GuruFocus
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA)
2/28/2025 - GuruFocus
Vanda Pharmaceuticals (VNDA, $4.71) Moving Average Convergence Divergence (MACD) Histogram turned positive on February 26, 2025
2/27/2025 - Tickeron - Stocks
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA)
2/27/2025 - GuruFocus
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Acquires 10,000 Shares
2/27/2025 - MarketBeat
Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Buys 10,000 Shares of Stock
2/26/2025 - MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Allspring Global Investments Holdings LLC
2/26/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$198.77M
EBITDA (TTM)
-$32.53M
EBIT (TTM)
-$40.66M
Net Income (TTM)
-$18.90M
Balance Sheet
Total Assets (Q)
$656.20M
Total Debt (Q)
$12.36M
Total Liabilities (Q)
$117.66M
Book Value Per Share (Q)
$9.24
Cash Flow
Cash from Operations (TTM)
-$15.76M
Cash from Investing (TTM)
-$17.43M
Cash from Financing (TTM)
-$155.00K
Net Change in Cash (TTM)
-$33.51M
Filings
Filing Date
Friday, February 14, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.72
7-Day Total Return
3.12%
30-Day Total Return
9.49%
60-Day Total Return
7.36%
90-Day Total Return
8.77%
Year to Date Total Return
2.90%
1-Year Total Return
29.17%
2-Year Total Return
-20.13%
3-Year Total Return
-55.15%
5-Year Total Return
-51.56%
52-week Low
Mar 20, 2024 - $3.71
52-week High
Jun 13, 2024 - $6.75
Valuation
Market Cap
$288.66M - Micro Cap
Enterprise Value
-$73.62M
Price/Sales (TTM)
1.45
Price/Book (Q)
0.54
Dividends and Shares
Shares Outstanding
58.31M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.vandapharma.com
Phone Number
202 734 3400
Address
2200 Pennsylvania Avenue NW
Washington, DC 20037
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed... more
NASDAQ 03/13/2025 10:12AM Eastern Quotes delayed
Weiss Ratings